May 4th 2024
The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
AI Models in Prostate Cancer Tackle Treatment Disparities Facing African American Men
November 20th 2023In an interview with Peers & Perspectives in Oncology, Rana McKay, MD, explains how an AI model can affect the disparities faced by racial minority groups and the wider adoption of AI in the prostate cancer space.
Read More
Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPC
October 22nd 2023Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Read More
Garmezy Reviews Efficacy, Safety, and Quality of Life for Cabazitaxel in mCRPC
October 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, discussed trial data that guides when to use cabazitaxel for patients with metastatic castration-resistant prostate cancer.
Read More
Petrylak Reviews Results From KEYNOTE-921 in mCRPC
September 28th 2023Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Watch
In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care
September 27th 2023Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
Read More
Bryce Reviews PARP Inhibitor Combination Trials in Prostate Cancer
September 27th 2023During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.
Read More
Analyzing Therapeutic Sequencing in Metastatic Prostate Cancer
September 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.
Read More
Safety Results with Cabazitaxel Support Wider Use in mCRPC
September 8th 2023In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.
Read More
Morgans and Choudhury Break Down Prostate Cancer Treatment for Heavily Pretreated Patients
August 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.
Read More
FDA to Quickly Review sNDA for Enzalutamide in nmCSPC With High-Risk BCR
August 23rd 2023The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.
Read More